



## Andreas Kerschbaumer

Postdoctoral Scholar, Immunology and Rheumatology

 Curriculum Vitae available Online

### Bio

---

#### BIO

Dr. Andreas Kerschbaumer is a postdoctoral scholar in the Division of Immunology and Rheumatology at Stanford University, conducting research in the Robinson and Khatri Labs. His work integrates clinical rheumatology with computational and systems immunology, applying meta-analytic techniques on transcriptomic datasets to uncover mechanisms of autoimmunity and improve therapeutic strategies in rheumatology.

He trained in internal medicine and rheumatology at the Medical University of Vienna, Department of Medicine III, Division of Rheumatology, where he also completed his PhD under Professors Smolen and Aletaha on treatment outcomes in inflammatory arthritis, followed by his habilitation on strategies to optimize the interpretation of clinical trial data in rheumatoid and psoriatic arthritis.

Dr. Kerschbaumer has been actively engaged with the European Alliance of Associations for Rheumatology (EULAR), contributing as Fellow, Methodologist, and Co-Methodologist to multiple international taskforces, including the 2019, 2022, and 2025 rheumatoid arthritis recommendations and the 2019 and 2023 psoriatic arthritis recommendations. He is currently a member of the EULAR Quality of Care Committee and serves as Co-Abstract Chair of the ACR Rheumatoid Arthritis abstract committee.

#### STANFORD ADVISORS

- William Robinson, Postdoctoral Faculty Sponsor

### Research & Scholarship

---

#### LAB AFFILIATIONS

- William Robinson, Robinson Lab (5/1/2025)
- Purvesh Khatri, Khatri Lab (5/1/2025)

### Publications

---

#### PUBLICATIONS

- **EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.** *Annals of the rheumatic diseases*  
Smolen, J. S., Edwards, C. J., Konzett, V., Laskou, F., Aletaha, D., Caporali, R., Dörner, T., Hyrich, K. L., Mateus, E., Pope, J. E., Primdahl, J., de Souza, S., Stamm, et al  
2026
- **Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis.** *Annals of the rheumatic diseases*  
Kerschbaumer, A., Steiner, M., Pruckner, P., Wildner, B., Maad, M., Smolen, J. S., Aletaha, D.

2025

- **Global Recruiting Patterns Affect Placebo Response Rates In Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis.** *Arthritis & rheumatology (Hoboken, N.J.)*  
Kerschbaumer, A., Steiner, M., Khalili, S., Shehab, A., Jordanov, A., Wildner, B., Maad, M., Smolen, J. S., Aletaha, D.  
2025
- **Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis.** *Annals of the rheumatic diseases*  
Kerschbaumer, A., Rivai, Z. I., Smolen, J. S., Aletaha, D.  
2022; 81 (10): 1374-1378
- **Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology.** *Nature medicine*  
Kerschbaumer, A., Smolen, J. S., Herkner, H., Stefanova, T., Chwala, E., Aletaha, D.  
2020; 26 (6): 974-980
- **The effects of structural damage on functional disability in psoriatic arthritis.** *Annals of the rheumatic diseases*  
Kerschbaumer, A., Baker, D., Smolen, J. S., Aletaha, D.  
2017; 76 (12): 2038-2045
- **Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis.** *Annals of the rheumatic diseases*  
Laskou, F., Konzett, V., Smolen, J. S., Edwards, C. J., Aletaha, D., van der Heijde, D., Winthrop, K. L., Takeuchi, T., Caporali, R., Verschueren, P., Pope, J. E., Hyrich, K., de Souza, et al  
2026
- **An international, multicentre, interventional, randomised, assessor-blinded trial to MAXimise the METHotrexate therapy potential in patients with active rheumatoid arthritis (MethMax trial): study protocol for a randomised controlled trial.** *Trials*  
Anderle, K., Sieghart, D., Durechova, M., Bonnay, F., Kerschbaumer, A., Chatzidionysiou, K., Knevel, R., Pitzalis, C., Lillegraven, S., Haavardsholm, E. A., Kristianslund, E. K., Codreanu, C., Popescu, et al  
2026
- **Response to 'Correspondence on 'Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update' by Nash et al.' by Telliez et al.** *Annals of the rheumatic diseases*  
Nash, P., Kerschbaumer, A., Konzett, V., Winthrop, K., Smolen, J. S.  
2026; 85 (3): e29-e30
- **Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024.** *Annals of the rheumatic diseases*  
Winthrop, K. L., Bathon, J., Kerschbaumer, A., Isaacs, J. D., Mease, P., Gottenberg, J. E., Crow, M. K., Kay, J., Crofford, L., Baraliakos, X., Bykerk, V., Siebert, S., Kloppenburg, et al  
2025; 84 (6): 927-936
- **Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statement.** *Annals of the rheumatic diseases*  
Konzett, V., Smolen, J. S., Nash, P., Winthrop, K., Aletaha, D., Dörner, T., Fleischmann, R., Tanaka, Y., Primdahl, J., Baraliakos, X., McInnes, I. B., Trauner, M., Sattar, et al  
2025; 84 (5): 697-715
- **Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.** *Annals of the rheumatic diseases*  
Nash, P., Kerschbaumer, A., Konzett, V., Aletaha, D., Dörner, T., Fleischmann, R., McInnes, I., Primdahl, J., Sattar, N., Tanaka, Y., Trauner, M., Winthrop, K., de Wit, et al  
2025; 84 (5): 664-679
- **Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement.** *Annals of the rheumatic diseases*  
Konzett, V., Smolen, J. S., Nash, P., Aletaha, D., Winthrop, K., Dörner, T., Fleischmann, R., Tanaka, Y., Primdahl, J., Baraliakos, X., McInnes, I. B., Trauner, M., Sattar, et al  
2025; 84 (5): 680-696
- **Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.** *Annals of the rheumatic diseases*

Kerschbaumer, A., Smolen, J. S., Ferreira, R. J., Bertheussen, H., Baraliakos, X., Aletaha, D., McGonagle, D. G., van der Heijde, D., McInnes, I. B., Esbensen, B. A., Winthrop, K. L., Boehncke, W. H., Schoones, et al  
2024; 83 (6): 760-774

- **EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.** *Annals of the rheumatic diseases*  
Gossec, L., Kerschbaumer, A., Ferreira, R. J., Aletaha, D., Baraliakos, X., Bertheussen, H., Boehncke, W. H., Esbensen, B. A., McInnes, I. B., McGonagle, D., Winthrop, K. L., Balanescu, A., Balint, et al  
2024; 83 (6): 706-719
- **Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.** *Annals of the rheumatic diseases*  
Winthrop, K. L., Mease, P., Kerschbaumer, A., Voll, R. E., Breedveld, F. C., Smolen, J. S., Gottenberg, J. E., Baraliakos, X., Kiener, H. P., Aletaha, D., Isaacs, J. D., Buch, M. H., Crow, et al  
2024; 83 (4): 409-416
- **Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review.** *Rheumatology (Oxford, England)*  
Hysa, E., Bond, M., Ehlers, L., Camellino, D., Falzon, L., Dejaco, C., Buttgereit, F., Aletaha, D., Kerschbaumer, A.  
2024; 63 (2): 285-297
- **Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.** *Annals of the rheumatic diseases*  
Bonelli, M., Kerschbaumer, A., Kastrati, K., Ghoreschi, K., Gadina, M., Heinz, L. X., Smolen, J. S., Aletaha, D., O'Shea, J., Laurence, A.  
2024; 83 (2): 139-160
- **Definition of rheumatoid arthritis flare based on SDAI and CDAI.** *Annals of the rheumatic diseases*  
Konzett, V., Kerschbaumer, A., Smolen, J. S., Kristianslund, E. K., Provan, S. A., Kvien, T. K., Aletaha, D.  
2024; 83 (2): 169-176
- **Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.** *Annals of the rheumatic diseases*  
Dejaco, C., Kerschbaumer, A., Aletaha, D., Bond, M., Hysa, E., Camellino, D., Ehlers, L., Abril, A., Appenzeller, S., Cid, M. C., Dasgupta, B., Duftner, C., Grayson, et al  
2024; 83 (1): 48-57
- **Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis.** *Annals of the rheumatic diseases*  
Konzett, V., Kerschbaumer, A., Smolen, J. S., Aletaha, D.  
2024; 83 (1): 58-64
- **Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.** *Annals of the rheumatic diseases*  
Aletaha, D., Kerschbaumer, A., Kastrati, K., Dejaco, C., Dougados, M., McInnes, I. B., Sattar, N., Stamm, T. A., Takeuchi, T., Trauner, M., van der Heijde, D., Voshaar, M., Winthrop, et al  
2023; 82 (6): 773-787
- **Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis.** *Annals of the rheumatic diseases*  
Kerschbaumer, A., Stimakovits, N. M., Smolen, J. S., Stefanova, T., Chwala, E., Aletaha, D.  
2023; 82 (4): 476-482
- **Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls.** *Annals of the rheumatic diseases*  
Kartnig, F., Mrak, D., Simader, E., Tobudic, S., Radner, H., Mandl, P., Göschl, L., Hommer, N., Mayer, M., Hofer, P., Hummel, T., Deimel, T., Geßl, et al  
2023; 82 (2): 292-300
- **Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.** *Annals of the rheumatic diseases*  
Kerschbaumer, A., Sepriano, A., Bergstra, S. A., Smolen, J. S., van der Heijde, D., Caporali, R., Edwards, C. J., Verschueren, P., de Souza, S., Pope, J. E., Takeuchi, T., Hyrich, K. L., Winthrop, et al  
2023; 82 (1): 95-106

- **Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.** *Annals of the rheumatic diseases*  
Sepriano, A., Kerschbaumer, A., Bergstra, S. A., Smolen, J. S., van der Heijde, D., Caporali, R., Edwards, C. J., Verschueren, P., de Souza, S., Pope, J., Takeuchi, T., Hyrich, K., Winthrop, et al  
2023; 82 (1): 107-118
- **EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.** *Annals of the rheumatic diseases*  
Smolen, J. S., Landewé, R. B., Bergstra, S. A., Kerschbaumer, A., Sepriano, A., Aletaha, D., Caporali, R., Edwards, C. J., Hyrich, K. L., Pope, J. E., de Souza, S., Stamm, T. A., Takeuchi, et al  
2023; 82 (1): 3-18
- **Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.** *Annals of the rheumatic diseases*  
Bergstra, S. A., Sepriano, A., Kerschbaumer, A., van der Heijde, D., Caporali, R., Edwards, C. J., Verschueren, P., de Souza, S., Pope, J. E., Takeuchi, T., Hyrich, K. L., Winthrop, K. L., Aletaha, et al  
2023; 82 (1): 81-94
- **Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study.** *Annals of the rheumatic diseases*  
Mrak, D., Simader, E., Sieghart, D., Mandl, P., Radner, H., Perkmann, T., Haslacher, H., Mayer, M., Koblishcke, M., Hofer, P., Göschl, L., Kartnig, F., Deimel, et al  
2022; 81 (12): 1750-1756
- **Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial.** *Nature communications*  
Mrak, D., Sieghart, D., Simader, E., Tobudic, S., Radner, H., Mandl, P., Göschl, L., Koblishcke, M., Hommer, N., Wagner, A., Mayer, M., Schubert, L., Hartl, et al  
2022; 13 (1): 5362
- **A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.** *RMD open*  
Kastrati, K., Aletaha, D., Burmester, G. R., Chwala, E., Dejaco, C., Dougados, M., McInnes, I. B., Ravelli, A., Sattar, N., Stamm, T. A., Takeuchi, T., Trauner, M., van der Heijde, et al  
2022; 8 (2)
- **Response to: 'Correspondence on 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Fallon et al.** *Annals of the rheumatic diseases*  
Baraliakos, X., Gossec, L., McInnes, I., Kerschbaumer, A., de Wit, M., Dougados, M., Primdahl, J., van der Heijde, D., Smolen, J. S.  
2022; 81 (9): e174
- **Response to: 'Comment on: 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Gossec et al' by Wei et al.** *Annals of the rheumatic diseases*  
Gossec, L., Baraliakos, X., McInnes, I., Kerschbaumer, A., de Wit, M., Dougados, M., Primdahl, J., van der Heijde, D., Smolen, J. S.  
2022; 81 (8): e139
- **Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis.** *Rheumatology (Oxford, England)*  
Studenic, P., Bond, G., Kerschbaumer, A., Bécède, M., Pavelka, K., Karateev, D., Stieger, J., Puchner, R., Mueller, R. B., Puchhammer-Stöckl, E., Durechova, M., Loiskandl, M., Perkmann, et al  
2022; 61 (7): 2815-2825
- **Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis.** *Annals of the rheumatic diseases*  
van Ouwkerk, L., Palmowski, A., Nevins, I. S., Buttgerit, F., Verschueren, P., Smolen, J. S., Landewé, R. B., Bijlsma, J. J., Kerschbaumer, A., Westhovens, R., Huizinga, T. W., Allaart, C. F., Bergstra, et al  
2022; 81 (7): 937-943
- **Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.** *Annals of the rheumatic diseases*  
Bonelli, M., Radner, H., Kerschbaumer, A., Mrak, D., Durechova, M., Stieger, J., Husic, R., Mandl, P., Smolen, J. S., Dejaco, C., Aletaha, D.  
2022; 81 (6): 838-844

- **Segmental endobronchial valve therapy for a vasculitis-induced emphysema.** *Respiratory medicine case reports*  
Bal, C., Göschl, L., Milos, R. I., Gerstbrein, K., Kerschbaumer, A., Idzko, M., Gompelmann, D.  
2022; 37: 101650
- **Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies.** *Annals of the rheumatic diseases*  
Siddle, H. J., Chapman, L. S., Mankia, K., Zăbălan, C., Kouloumas, M., Raza, K., Falahee, M., Kerry, J., Kerschbaumer, A., Aletaha, D., Emery, P., Richards, S. H.  
2022; 81 (2): 159-168
- **Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free?** *Annals of the rheumatic diseases*  
McGonagle, D. G., Zabotti, A., Watad, A., Bridgwood, C., De Marco, G., Kerschbaumer, A., Aletaha, D.  
2022; 81 (1): 7-10
- **EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.** *Annals of the rheumatic diseases*  
Mankia, K., Siddle, H. J., Kerschbaumer, A., Alpizar Rodriguez, D., Catrina, A. I., Cañete, J. D., Cope, A. P., Daien, C. I., Deane, K. D., El Gabalawy, H., Finckh, A., Holers, V. M., Koloumas, et al  
2021; 80 (10): 1286-1298
- **A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.** *RMD open*  
Mankia, K., Siddle, H., Di Matteo, A., Alpizar-Rodríguez, D., Kerry, J., Kerschbaumer, A., Aletaha, D., Emery, P.  
2021; 7 (3)
- **Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.** *Annals of the rheumatic diseases*  
Nash, P., Kerschbaumer, A., Dörner, T., Dougados, M., Fleischmann, R. M., Geissler, K., McInnes, I., Pope, J. E., van der Heijde, D., Stoffer-Marx, M., Takeuchi, T., Trauner, M., Winthrop, et al  
2021; 80 (1): 71-87
- **Hand X-ray examination in two planes is not required for radiographic assessment of hand osteoarthritis.** *Therapeutic advances in musculoskeletal disease*  
Staats, K., Sunk, I. G., Weidekamm, C., Kerschbaumer, A., Bécède, M., Supp, G., Stamm, T., Windhager, R., Smolen, J. S., Bobacz, K.  
2020; 12: 1759720X20934934
- **Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al.** *Arthritis & rheumatology (Hoboken, N.J.)*  
Kerschbaumer, A., Smolen, J. S., Aletaha, D.  
2020; 72 (7): 1227-1229
- **Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.** *Annals of the rheumatic diseases*  
Sepriano, A., Kerschbaumer, A., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I. B., Bijlsma, J. W., Burmester, G. R., de Wit, M., Falzon, L., Landewé, R.  
2020; 79 (6): 760-770
- **Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.** *Annals of the rheumatic diseases*  
Kerschbaumer, A., Sepriano, A., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I. B., Bijlsma, J. W., Burmester, G. R., de Wit, M., Falzon, L., Landewé, R.  
2020; 79 (6): 744-759
- **EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.** *Annals of the rheumatic diseases*  
Gossec, L., Baraliakos, X., Kerschbaumer, A., de Wit, M., McInnes, I., Dougados, M., Primdahl, J., McGonagle, D. G., Aletaha, D., Balanescu, A., Balint, P. V., Bertheussen, H., Boehncke, et al  
2020; 79 (6): 700-712
- **EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.** *Annals of the rheumatic diseases*

Smolen, J. S., Landewé, R. B., Bijlsma, J. W., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., Aletaha, D., Aringer, M., Askling, et al  
2020; 79 (6): 685-699

- **Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.** *Annals of the rheumatic diseases*  
Kerschbaumer, A., Smolen, J. S., Dougados, M., de Wit, M., Primdahl, J., McInnes, I., van der Heijde, D., Baraliakos, X., Falzon, L., Gossec, L.  
2020; 79 (6): 778-786
- **Targeting p19 in psoriatic arthritis: more than just another therapeutic approach?** *Lancet (London, England)*  
Kerschbaumer, A., Aletaha, D.  
2020; 395 (10230): 1091-1093
- **Risk profiling for a refractory course of rheumatoid arthritis.** *Seminars in arthritis and rheumatism*  
Bécède, M., Alasti, F., Gessl, I., Haupt, L., Kerschbaumer, A., Landesmann, U., Loiskandl, M., Supp, G. M., Smolen, J. S., Aletaha, D.  
2019; 49 (2): 211-217
- **Disease activity assessment in patients with psoriatic arthritis.** *Best practice & research. Clinical rheumatology*  
Kerschbaumer, A., Smolen, J. S., Aletaha, D.  
2018; 32 (3): 401-414
- **Tofacitinib for Psoriatic Arthritis.** *The New England journal of medicine*  
Aletaha, D., Kerschbaumer, A., Smolen, J. S.  
2018; 378 (8): 775
- **The Case | Myeloid bodies in the kidney biopsy of a patient with systemic lupus erythematosus.** *Kidney international*  
Bojic, M., Kozakowski, N., Bécède, M., Kerschbaumer, A., Bobacz, K.  
2017; 92 (1): 271-272
- **Fever of unknown origin (FUO) revised.** *Wiener klinische Wochenschrift*  
Unger, M., Karanikas, G., Kerschbaumer, A., Winkler, S., Aletaha, D.  
2016; 128 (21-22): 796-801
- **An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets.** *Wiener klinische Wochenschrift*  
Kerschbaumer, A., Fenzl, K. H., Erlacher, L., Aletaha, D.  
2016; 128 (21-22): 791-795